We have determined that some signaling pathways such as RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 are critically involved in the sensitivity of various cancers such as; hematopoietic, breast, prostate and pancreatic to chemotherapy, radiotherapy and targeted therapy [2–8]. This evidence concerns the gene AKT1 and cancer.